
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video) - 2
Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video) - 3
From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected - 4
Pick Your #1 Japanese Food - 5
ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
Michael Jordan donates $10M to North Carolina medical center in honor of his mother
EU Council president: Ukraine should receive binding guarantees
6 Arranging Administrations to Change Your Open air Space
James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
They died 'doing what they loved': The stories of workers in their 80s who died on the job













